ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

1:00PM-2:30PM: Abstract Number: 2553

Predictors of Biologic and Targeted Synthetic DMARD Initiation for Rheumatoid Arthritis Across Underserved Patient Groups: Insights from a National Cohort Study

Abstracts: Healthcare Disparities in Rheumatology

1:00PM-2:30PM: Abstract Number: 2554

Prevalence and Clinical Characteristics of Vasculitis in the Alaska Native and American Indian Peoples of Alaska

Abstracts: Healthcare Disparities in Rheumatology

1:00PM-2:30PM: Abstract Number: 2541

Probiotic Modulation of Gut Microbiota Mitigates Early Rheumatoid Arthritis Progression: Insights from Pre-Clinical Models

Abstracts: RA – Animal Models

1:00PM-2:30PM: Abstract Number: 2564

Providing Optimal and Equitable Osteoporosis Treatment Using a Programmatic Approach -A 20 Year Longitudinal Study

Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science

1:00PM-2:30PM: Abstract Number: 2559

Relationship Between Serum Urate and Changes in Dual Energy Computed Tomography MSU Crystal Volume over One Year in People with Gout: An Individual Participant Data Analysis

Abstracts: Metabolic & Crystal Arthropathies

1:00PM-2:30PM: Abstract Number: 2586

Results from the Biopsy Driven Ebio Study: Entheseal Tissue Signature in Response to IL-17 Blockade in Psoriatic Arthritis

Abstracts: SpA Including PsA – Treatment II

1:00PM-2:30PM: Abstract Number: 2579

Risk of End-Stage Renal Disease Among Patients with Lupus Nephritis on GLP-1 Receptor Agonists: A Retrospective Cohort Study

Abstracts: SLE – Treatment II: Non-Cellular Lupus Therapeutics

1:00PM-2:30PM: Abstract Number: 2580

Safety and Efficacy of Subcutaneous Ianalumab (VAY736) for up to 68 Weeks in Patients with Systemic Lupus Erythematosus: Results from Phase 2 Study

Abstracts: SLE – Treatment II: Non-Cellular Lupus Therapeutics

1:00PM-2:30PM: Abstract Number: 2578

Safety, Biomarker Response, and Efficacy of E6742, a Dual Antagonist of Toll-Like Receptor 7 and 8, in a First-in-Patient, Randomized, Double-Blind, Phase1/2 Study in Systemic Lupus Erythematosus

Abstracts: SLE – Treatment II: Non-Cellular Lupus Therapeutics

1:00PM-2:30PM: Abstract Number: 2537

Sjögren’s Disease and Non-Sjögren’s Sicca Patient Subsets Exhibit Cell Type-specific Transcriptional Dysregulations That May Identify Early Molecular Predictors of Disease Transition

Abstracts: Genetics, Genomics & Proteomics

1:00PM-2:30PM: Abstract Number: 2544

Spatial Transcriptomics Suggests Synovial Macrophage Niches Are Sexually Dimorphic in a Mouse Inflammatory Arthritis Model

Abstracts: RA – Animal Models

1:00PM-2:30PM: Abstract Number: 2574

Tear Biomarkers for Monitoring Disease Activity and Progression of Noninfectious Chronic Anterior Uveitis in Children

Abstracts: Pediatric Rheumatology – Clinical I

1:00PM-2:30PM: Abstract Number: 2539

Telocytes Integrated into Mast Cells and Joint-Draining Lymphatic Vessels Potentially Regulate Lymphatic Clearance

Abstracts: RA – Animal Models

1:00PM-2:30PM: Abstract Number: 2592

The Effects of Early Life Trauma and Socioeconomic Position on Systemic Lupus Erythematosus Risk in Adulthood

Abstracts: ARP Interprofessional I: Epidemiology & Methods

1:00PM-2:30PM: Abstract Number: 2535

The Lipidomic and Proteomic Profiles in Antiphospholipid Syndrome Patients Are Intricately Linked to Disease Pathogenesis and Modulated by Ubiquinol Supplementation

Abstracts: Genetics, Genomics & Proteomics

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].